Purpose of the TargetAMD project is to develop a non-viral gene therapeutic approach for the treatment of Age-Related Macular Degeneration (AMD).
Science »
In AMD an innerocular protein imbalance is one reason for increased neovascularisation which deteriorates vision up to blindness. TargetAMD uses the Sleeping Beauty transposon system to modify the genome of autologous pigment epithelial cells and justify a protein re-balancing. Transfection and re-transplantation of the gene modified cells will be performed in one surgical session.
Goal of the TargetAMD project is to improve significantly the quality of life for patients suffering from Age-related Macular Degeneration (AMD).
Patient »
The new developed therapy will reduce the risk of side effects, the frequency of treatment and the effort for the patient. It transfers the synergistic power of academic, clinical and industrial cooperation to the scientific arena, and opens new markets for the clinical application of transposon-based gene therapy.

News

2019.05.09	Ethical approval for clinical trial from the Commission cantonal d'éthique de la recherche, CCER, of Geneva
2018.02.22	The seventh TargetAMD peer-reviewed paper is published in high ranked journal
2018.01.11	Our partner Daniel Scherman, CNRS, is the laureate 2017 of the Emilia Valori prize of applied sciences (chemistry, biology and medicine and their application)